51. Beta-Lactam/Beta-Lactamase Inhibitor Therapy for Potential AmpC-Producing Organisms: A Systematic Review and Meta-Analysis
- Author
-
Emily G. McDonald, Matthew P. Cheng, Samuel De l'Étoile-Morel, Cedric P. Yansouni, Patrick N A Harris, Robyn S Lee, Koray Demir, Todd C. Lee, and Alexandre Pellan Cheng
- Subjects
0301 basic medicine ,Carbapenem ,medicine.medical_treatment ,030106 microbiology ,Providencia ,Serratia ,Beta-Lactam ,carbapenem ,Microbiology ,03 medical and health sciences ,0302 clinical medicine ,Morganella ,030225 pediatrics ,polycyclic compounds ,medicine ,bacteremia ,Beta-Lactamase Inhibitors ,Citrobacter ,biology ,business.industry ,Brief Report ,Enterobacter ,biochemical phenomena, metabolism, and nutrition ,biology.organism_classification ,3. Good health ,Infectious Diseases ,Oncology ,ampC ,Beta-lactamase ,bacteria ,business ,beta-lactamase ,medicine.drug - Abstract
The optimal treatment for potential AmpC-producing Enterobacteriaceae, including Serratia, Providencia, Citrobacter, Enterobacter, and Morganella species, remains unknown. An updated systematic review and meta-analysis of studies comparing beta-lactam/beta-lactamase inhibitors with carbapenems in the treatment of bloodstream infections with these pathogens found no significant difference in 30-day mortality (OR, 1.13; 95% CI, 0.58 – 2.20)., The optimal treatment of bloodstream infections caused by potential AmpC-producing organisms is unsettled. A systematic review with meta-analysis found no significant difference in 30-day mortality in patients who were treated with beta-lactam/beta-lactamase inhibitors compared with carbapenems.
- Published
- 2019
- Full Text
- View/download PDF